Key result
DG-041, a selective EP3 antagonist, inhibited PGE2-facilitated platelet aggregation without prolonging bleeding time in rats, suggesting a superior safety profile to P2Y12 antagonists.
Why the study?
Does DG-041 inhibit platelet aggregation without prolonging bleeding time in preclinical models?
Population
In vitro/ex vivo platelets and rat models
Comparison
DG-041, alone or co-administered with clopidogrel vs Clopidogrel alone or control
Design
Preclinical
Authors
Loading...
May support EP3 antagonism for safer antiplatelet effects; leaves open human trials to confirm translation.
Does DG-041 inhibit platelet aggregation without prolonging bleeding time in preclinical models?
DG-041 is a novel EP3 antagonist that inhibits platelet aggregation without increasing bleeding risk in preclinical models, suggesting a potentially safer antiplatelet profile.
Singh et al. (2009) studied Atherothrombosis. DG-041 vs. clopidogrel was evaluated on PGE2 facilitation of platelet aggregation and bleeding time. DG-041, a selective EP3 antagonist, inhibited PGE2-facilitated platelet aggregation without prolonging bleeding time in rats, suggesting a superior safety profile to P2Y12 antagonists.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: